Thus, European guidelines for non-small-cell lung cancer (NSCLC) management encourage a wide coverage of broader molecular profiling including conventional mutations such as exons 18-21 EGFR as well as rarer driver events for which specific drugs may already be available or accessible through clinical trials [4]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.